Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge.
To own OSI Systems, you need to believe in its ability to convert a growing backlog into stable cash generation while managing contract and execution risks. The new US$40,000,000 medical OEM award broadens the healthcare footprint but does not materially change the near term focus on managing working capital swings and exposure to large, lumpy government and infrastructure contracts.
The most relevant recent announcement alongside this medical contract is the solid Q2 FY2026 result, with higher revenue and net income. Together, ongoing contract wins in security and optoelectronics and improving earnings help underpin the backlog story, even as healthcare margins and the ramp up of new manufacturing programs remain key swing factors for profitability.
However, investors should not overlook the risk that heavy dependence on large government and sovereign customers could...
Read the full narrative on OSI Systems (it's free!)
OSI Systems' narrative projects $2.1 billion revenue and $227.2 million earnings by 2029. This requires 5.7% yearly revenue growth and a roughly $74 million earnings increase from $153.1 million today.
Uncover how OSI Systems' forecasts yield a $300.00 fair value, a 9% upside to its current price.
Simply Wall St Community members have published three fair value estimates between US$203.66 and US$300 per share, underscoring how far opinions can spread. When you set these community views against OSI Systems’ reliance on concentrated contracts and government funding cycles, it becomes even more important to compare multiple perspectives before forming a view.
Explore 3 other fair value estimates on OSI Systems - why the stock might be worth as much as 9% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com